• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

共无定形筛选用于提高难溶性米拉贝隆的溶解度及其分子间相互作用和溶解行为的研究。

Co-Amorphous Screening for the Solubility Enhancement of Poorly Water-Soluble Mirabegron and Investigation of Their Intermolecular Interactions and Dissolution Behaviors.

作者信息

An Ji-Hun, Lim Changjin, Kiyonga Alice Nguvoko, Chung In Hwa, Lee In Kyu, Mo Kilwoong, Park Minho, Youn Wonno, Choi Won Rak, Suh Young-Ger, Jung Kiwon

机构信息

Institute of Pharmaceutical Sciences, College of Pharmacy, CHA University, Sungnam 13844, Korea.

R&D Center, Sungwun Pharmacopia, Seoul 05836, Korea.

出版信息

Pharmaceutics. 2018 Sep 5;10(3):149. doi: 10.3390/pharmaceutics10030149.

DOI:10.3390/pharmaceutics10030149
PMID:30189645
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6161252/
Abstract

In the present study, the screening of Mirabegron (MBR) co-amorphous was performed to produce water-soluble and thermodynamically stable MBR co-amorphous with the purpose of overcoming the water solubility problem of MBR. MBR is Biopharmaceutics Classification System (BCS) class II drug used for the treatment of an overreactive bladder. The co-amorphous screening was carried out by means of the vacuum evaporation crystallization technique in methanol solvent using three water-soluble carboxylic acids, characterized by a pKa difference greater than 3 with MBR such as fumaric acid (FA), l-pyroglutamic acid (PG), and citric acid (CA). Powder X-ray diffraction (PXRD) results suggested that all solid materials produced at MBR-FA (1 equivalent (eq.)/1 equivalent (eq.)), MBR-PG (1 eq./1 eq.), and MBR-CA (1 eq./1 eq.) conditions were amorphous state solid materials. Furthermore, by means of solution-state nuclear magnetic resonance (NMR) (¹H, C, and 2D) and attenuated total reflection Fourier transform infrared (ATR-FTIR) spectroscopy, we could assess that MBR and carboxylic acid molecules were linked via ionic interactions to produce MBR co-amorphous. Besides, solid-state cross polarization (CP)/magic angle spinning (MAS) C-NMR analysis was conducted for additional assessment of MBR co-amorphous. Afterwards, dissolution tests of MBR co-amorphouses, MBR crystalline solid, and MBR amorphous were carried out for 12 h to evaluate and to compare their solubilities, dissolution rates, and phase transformation phenomenon. Here, the results suggested that MBR co-amorphouses displayed more than 57-fold higher aqueous solubility compared to MBR crystalline solid, and PXRD monitoring result suggested that MBR co-amorphouses were able to maintain their amorphous state for more than 12 h. The same results revealed that MBR amorphous exhibited increased solubility of approximatively 6.7-fold higher compared to MBR crystalline solid. However, the PXRD monitoring result suggested that MBR amorphous undergo rapid phase transformation to crystalline form in just 35 min and that within an hour all MBR amorphous are completely converted to crystalline solid. Accordingly, the increase in MBR co-amorphous' solubility was attributed to the presence of ionic interactions in MBR co-amorphous molecules. Moreover, from the differential scanning calorimetry (DSC) monitoring results, we predicted that the high glass transition temperature () of MBR co-amorphous compared to MBR amorphous was the main factor influencing the phase stability of MBR co-amorphous.

摘要

在本研究中,进行了米拉贝隆(MBR)共无定形物的筛选,以制备具有水溶性且热力学稳定的MBR共无定形物,目的是克服MBR的水溶性问题。MBR是一种生物药剂学分类系统(BCS)II类药物,用于治疗膀胱过度活动症。共无定形物筛选是在甲醇溶剂中通过真空蒸发结晶技术进行的,使用了三种水溶性羧酸,其与MBR的pKa差值大于3,如富马酸(FA)、L-焦谷氨酸(PG)和柠檬酸(CA)。粉末X射线衍射(PXRD)结果表明,在MBR-FA(1当量(eq.)/1当量(eq.))、MBR-PG(1 eq./1 eq.)和MBR-CA(1 eq./1 eq.)条件下制备的所有固体材料均为无定形态固体材料。此外,通过溶液态核磁共振(NMR)(¹H、C和二维)以及衰减全反射傅里叶变换红外(ATR-FTIR)光谱,我们可以评估MBR与羧酸分子通过离子相互作用连接以产生MBR共无定形物。此外,还进行了固态交叉极化(CP)/魔角旋转(MAS)C-NMR分析以对MBR共无定形物进行额外评估。之后,对MBR共无定形物、MBR结晶固体和MBR无定形物进行了12小时的溶出试验,以评估和比较它们的溶解度、溶出速率和相变现象。在此,结果表明,与MBR结晶固体相比,MBR共无定形物的水溶性高出57倍以上,并且PXRD监测结果表明MBR共无定形物能够在超过12小时内保持其无定形态。相同的结果表明,与MBR结晶固体相比,MBR无定形物的溶解度增加了约6.7倍。然而,PXRD监测结果表明,MBR无定形物在仅35分钟内就迅速相转变为结晶形式,并且在一小时内所有MBR无定形物都完全转化为结晶固体。因此,MBR共无定形物溶解度的增加归因于MBR共无定形物分子中存在离子相互作用。此外,从差示扫描量热法(DSC)监测结果来看,我们预测MBR共无定形物与MBR无定形物相比具有较高的玻璃化转变温度()是影响MBR共无定形物相稳定性的主要因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f26e/6161252/558bd689ebad/pharmaceutics-10-00149-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f26e/6161252/9de32a2b1295/pharmaceutics-10-00149-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f26e/6161252/0ddfd88f989c/pharmaceutics-10-00149-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f26e/6161252/363455f52227/pharmaceutics-10-00149-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f26e/6161252/25194ab06a95/pharmaceutics-10-00149-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f26e/6161252/4ed1116ce333/pharmaceutics-10-00149-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f26e/6161252/c9678dd46fa1/pharmaceutics-10-00149-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f26e/6161252/5d587b51451b/pharmaceutics-10-00149-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f26e/6161252/558bd689ebad/pharmaceutics-10-00149-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f26e/6161252/9de32a2b1295/pharmaceutics-10-00149-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f26e/6161252/0ddfd88f989c/pharmaceutics-10-00149-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f26e/6161252/363455f52227/pharmaceutics-10-00149-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f26e/6161252/25194ab06a95/pharmaceutics-10-00149-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f26e/6161252/4ed1116ce333/pharmaceutics-10-00149-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f26e/6161252/c9678dd46fa1/pharmaceutics-10-00149-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f26e/6161252/5d587b51451b/pharmaceutics-10-00149-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f26e/6161252/558bd689ebad/pharmaceutics-10-00149-g008.jpg

相似文献

1
Co-Amorphous Screening for the Solubility Enhancement of Poorly Water-Soluble Mirabegron and Investigation of Their Intermolecular Interactions and Dissolution Behaviors.共无定形筛选用于提高难溶性米拉贝隆的溶解度及其分子间相互作用和溶解行为的研究。
Pharmaceutics. 2018 Sep 5;10(3):149. doi: 10.3390/pharmaceutics10030149.
2
Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.制备无定形呋塞米钠盐可提高溶解度和溶出速率,并导致大鼠口服给药后的 Tmax 更快。
Eur J Pharm Biopharm. 2013 Nov;85(3 Pt B):942-51. doi: 10.1016/j.ejpb.2013.09.002. Epub 2013 Sep 27.
3
Characterization of Solid Dispersion of Itraconazole Prepared by Solubilization in Concentrated Aqueous Solutions of Weak Organic Acids and Drying.通过在弱有机酸浓水溶液中增溶并干燥制备的伊曲康唑固体分散体的表征
Pharm Res. 2016 Jun;33(6):1456-71. doi: 10.1007/s11095-016-1890-8. Epub 2016 Mar 7.
4
Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.氨基酸作为低水溶解性药物的共无定形稳定剂——第 1 部分:制备、稳定性和溶出度的提高。
Eur J Pharm Biopharm. 2013 Nov;85(3 Pt B):873-81. doi: 10.1016/j.ejpb.2013.03.014. Epub 2013 Mar 26.
5
Co-amorphous formulation of dipyridamole with p-hydroxybenzoic acid: Underlying molecular mechanisms, physical stability, dissolution behavior and pharmacokinetic study.双嘧达莫与对羟基苯甲酸的共无定形制剂:潜在分子机制、物理稳定性、溶出行为及药代动力学研究
Eur J Pharm Biopharm. 2023 Mar;184:139-149. doi: 10.1016/j.ejpb.2023.01.018. Epub 2023 Jan 26.
6
A Novel Desloratadine-Benzoic Acid Co-Amorphous Solid: Preparation, Characterization, and Stability Evaluation.一种新型地氯雷他定-苯甲酸共无定形固体:制备、表征及稳定性评价。
Pharmaceutics. 2018 Jul 6;10(3):85. doi: 10.3390/pharmaceutics10030085.
7
Preparation and characterization of co-amorphous Ritonavir-Indomethacin systems by solvent evaporation technique: improved dissolution behavior and physical stability without evidence of intermolecular interactions.通过溶剂蒸发技术制备共无定形利托那韦-吲哚美辛体系及其表征:改善的溶解行为和物理稳定性,无分子间相互作用迹象
Eur J Pharm Sci. 2014 Oct 1;62:57-64. doi: 10.1016/j.ejps.2014.05.015. Epub 2014 May 28.
8
Incorporation of Complexation into a Coamorphous System Dramatically Enhances Dissolution and Eliminates Gelation of Amorphous Lurasidone Hydrochloride.将络合作用纳入共无定形系统可显著提高无定形盐酸鲁拉西酮的溶解性能并消除其胶凝作用。
Mol Pharm. 2020 Jan 6;17(1):84-97. doi: 10.1021/acs.molpharmaceut.9b00772. Epub 2019 Dec 16.
9
Spray drying ternary amorphous solid dispersions of ibuprofen - An investigation into critical formulation and processing parameters.喷雾干燥布洛芬三元无定形固体分散体:关键配方和工艺参数研究。
Eur J Pharm Biopharm. 2017 Nov;120:43-51. doi: 10.1016/j.ejpb.2017.08.005. Epub 2017 Aug 16.
10
Investigation for the amorphous state of ER-34122, a dual 5-lipoxygenase/cyclooxygenase inhibitor with poor aqueous solubility, in HPMC solid dispersion prepared by the solvent evaporation method.采用溶剂蒸发法制备的 ER-34122(一种具有较差水溶性的双重 5-脂氧合酶/环氧化酶抑制剂)HPMC 固体分散体的无定形状态研究。
Drug Dev Ind Pharm. 2013 Oct;39(10):1582-8. doi: 10.3109/03639045.2012.679279. Epub 2012 Apr 20.

引用本文的文献

1
Investigation of Mirabegron-loaded Nanostructured Lipid Carriers for Improved Bioabsorption: Formulation, Statistical Optimization, and In-Vivo Evaluation.米贝肟负载纳米结构脂质载体改善生物吸收的研究:制剂、统计优化和体内评价。
AAPS PharmSciTech. 2024 Sep 25;25(7):222. doi: 10.1208/s12249-024-02944-1.
2
Intestinal Absorption Site-Guided Development and Evaluation of Oral Disintegrating Controlled Release Tablets of Mirabegron.肠道吸收部位导向的米拉贝隆口腔速释控释片的研制与评价。
AAPS PharmSciTech. 2024 Jul 24;25(6):167. doi: 10.1208/s12249-024-02865-z.
3
Distinct Conformations of Mirabegron Determined by MicroED.

本文引用的文献

1
Recent advances in co-amorphous drug formulations.共无定形药物制剂的最新进展。
Adv Drug Deliv Rev. 2016 May 1;100:116-25. doi: 10.1016/j.addr.2015.12.009. Epub 2016 Jan 21.
2
Rheological and solid-state NMR assessments of copovidone/clotrimazole model solid dispersions.共聚维酮/克霉唑模型固体分散体的流变学和固态核磁共振评估
Int J Pharm. 2016 Mar 16;500(1-2):20-31. doi: 10.1016/j.ijpharm.2016.01.026. Epub 2016 Jan 15.
3
Formation Mechanism of Coamorphous Drug-Amino Acid Mixtures.共无定形药物-氨基酸混合物的形成机制
微电镜解析米拉贝隆的不同构象。
Adv Sci (Weinh). 2023 Dec;10(34):e2304476. doi: 10.1002/advs.202304476. Epub 2023 Oct 17.
4
Improved Pharmacokinetic Feasibilities of Mirabegron-1,2-Ethanedisulfonic Acid, Mirabegron-1,5-Naphthalenedisulfonic Acid, and Mirabegron-L-Pyroglutamic Acid as Co-Amorphous Dispersions in Rats and Mice.米拉贝隆-1,2-乙二磺酸、米拉贝隆-1,5-萘二磺酸和米拉贝隆-L-焦谷氨酸作为共无定形分散体在大鼠和小鼠体内的药代动力学可行性提高。
Pharmaceutics. 2023 Sep 4;15(9):2277. doi: 10.3390/pharmaceutics15092277.
5
Ternary Solid Dispersions: A Review of the Preparation, Characterization, Mechanism of Drug Release, and Physical Stability.三元固体分散体:制备、表征、药物释放机制及物理稳定性综述
Pharmaceutics. 2023 Aug 10;15(8):2116. doi: 10.3390/pharmaceutics15082116.
6
BX795-Organic Acid Coevaporates: Evaluation of Solid-State Characteristics, In Vitro Cytocompatibility and In Vitro Activity against HSV-1 and HSV-2.BX795与有机酸共蒸发物:固态特性、体外细胞相容性及抗单纯疱疹病毒1型和2型的体外活性评估
Pharmaceutics. 2021 Nov 12;13(11):1920. doi: 10.3390/pharmaceutics13111920.
7
Co-Amorphous Drug Formulations in Numbers: Recent Advances in Co-Amorphous Drug Formulations with Focus on Co-Formability, Molar Ratio, Preparation Methods, Physical Stability, In Vitro and In Vivo Performance, and New Formulation Strategies.共无定形药物制剂的量化:共无定形药物制剂的最新进展,重点关注共形成性、摩尔比、制备方法、物理稳定性、体外和体内性能以及新的制剂策略。
Pharmaceutics. 2021 Mar 15;13(3):389. doi: 10.3390/pharmaceutics13030389.
8
Pterostilbene Nanoparticles Downregulate Hypoxia-Inducible Factors in Hepatoma Cells Under Hypoxic Conditions.白皮杉醇纳米粒在低氧条件下下调肝癌细胞中的低氧诱导因子。
Int J Nanomedicine. 2021 Feb 5;16:867-879. doi: 10.2147/IJN.S282172. eCollection 2021.
9
Applying Supercritical Fluid Technology to Prepare Ibuprofen Solid Dispersions with Improved Oral Bioavailability.应用超临界流体技术制备具有改善口服生物利用度的布洛芬固体分散体。
Pharmaceutics. 2019 Feb 3;11(2):67. doi: 10.3390/pharmaceutics11020067.
10
Kinetics of the Solution-Mediated Polymorphic Transformation of the Novel l-Carnitine Orotate Polymorph, Form-II.新型左旋肉碱乳清酸盐多晶型物II型的溶液介导多晶型转变动力学
Pharmaceutics. 2018 Oct 1;10(4):171. doi: 10.3390/pharmaceutics10040171.
Mol Pharm. 2015 Jul 6;12(7):2484-92. doi: 10.1021/acs.molpharmaceut.5b00295. Epub 2015 Jun 23.
4
Amino acids as co-amorphous stabilizers for poorly water-soluble drugs--Part 2: molecular interactions.氨基酸作为低水溶解性药物的共无定形稳定剂-第 2 部分:分子相互作用。
Eur J Pharm Biopharm. 2013 Nov;85(3 Pt B):882-8. doi: 10.1016/j.ejpb.2013.03.026. Epub 2013 Apr 6.
5
Emerging trends in the stabilization of amorphous drugs.无定形药物稳定化的新兴趋势。
Int J Pharm. 2013 Aug 30;453(1):65-79. doi: 10.1016/j.ijpharm.2012.04.066. Epub 2012 Apr 28.
6
Development and validation of LC-MS/MS methods for the determination of mirabegron and its metabolites in human plasma and their application to a clinical pharmacokinetic study.建立并验证 LC-MS/MS 法测定人血浆中米拉贝隆及其代谢物的浓度及其在临床药代动力学研究中的应用。
J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Mar 1;887-888:102-11. doi: 10.1016/j.jchromb.2012.01.018. Epub 2012 Jan 26.
7
Characterization of cimetidine-piroxicam coprecipitate interaction using experimental studies and molecular dynamic simulations.采用实验研究和分子动力学模拟对西咪替丁-吡罗昔康共沉淀物相互作用进行表征。
AAPS PharmSciTech. 2010 Jun;11(2):952-8. doi: 10.1208/s12249-010-9461-5. Epub 2010 May 29.
8
Enhanced dissolution rate and synchronized release of drugs in binary systems through formulation: Amorphous naproxen-cimetidine mixtures prepared by mechanical activation.通过制剂提高二元体系中药物的溶出速率和同步释放:机械活化制备的无定形萘普生-西咪替丁混合物
J Control Release. 2009 May 21;136(1):45-53. doi: 10.1016/j.jconrel.2009.01.027. Epub 2009 Feb 10.
9
Physical characterization and stability of amorphous indomethacin and ranitidine hydrochloride binary systems prepared by mechanical activation.通过机械活化制备的无定形吲哚美辛和盐酸雷尼替丁二元体系的物理表征及稳定性
Eur J Pharm Biopharm. 2009 Jan;71(1):47-54. doi: 10.1016/j.ejpb.2008.06.022. Epub 2008 Jul 3.
10
Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs.固体分散体作为提高难溶性药物口服生物利用度的策略。
Drug Discov Today. 2007 Dec;12(23-24):1068-75. doi: 10.1016/j.drudis.2007.09.005. Epub 2007 Oct 30.